Remimazolam Besylate is the besylate ester form of remimazolam, a short-acting benzodiazepine derivative that is structurally related to midazolam, with sedative-hypnotic activity. Upon administration, remimazolam targets and binds to a specific site on the gamma-aminobutyric acid (GABA)-A-chloride ionophore receptor complex located on the neuronal membrane. Remimazolam Besylate is a small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated in sedation and has 1 investigational indication. This drug has a black box warning from the FDA. It is grouped under the following drug class(es): Benzodiazepines, Hypnotics and Sedatives. Its therapeutic use is listed as anesthetics. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Remimazolam Benzenesulfonate, Byfavo and anerem. It is listed as a controlled drug substance (Schedule IV). Its PubChem CID is 23658607.
Remimazolam besylate
| CAS No | 1001415-66-2 |
|---|---|
| Molecular Formula | C27H25BrN4O5S |
| Molecular Weight | 597.5 g/mol |
| Synonyms | benzenesulfonic acid;methyl 3-[(4S)-8-bromo-1-methyl-6-pyridin-2-yl-4H-imidazo[1,2-a][1,4]benzodiazepin-4-yl]propanoate |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Remimazolam Besylate is the besylate ester form of remimazolam, a short-acting benzodiazepine derivative that is structurally related to midazolam, with sedative-hypnotic activity.
The listed CAS number is 1001415-66-2.
The listed molecular formula is C27H25BrN4O5S.
The listed molecular weight is 597.5 g/mol.
benzenesulfonic acid;methyl 3-[(4S)-8-bromo-1-methyl-6-pyridin-2-yl-4H-imidazo[1,2-a][1,4]benzodiazepin-4-yl]propanoate.
The source lists Remimazolam Benzenesulfonate, Byfavo and anerem.